Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hormone Refractory Prostate Cancer: New Studies In Austria

29.03.2010
- Three clinical trials started at the Medical University of Vienna
- Commissioned by multinational pharmaceutical firms

The Medical University of Vienna has been commissioned by international pharmaceutical firms to conduct three clinical trials of the treatment of recurrent prostate tumors (hormone refractory prostate carcinomas). The new approaches comprise immunotherapy, hormone therapy and an augmented form of the current standard treatment with docetaxel.

Team leader Prof. Dr. Michael Krainer and his colleagues will concentrate primarily on tumors diagnosed late or those which recur after surgical interventions, and which do not (or no longer) respond to common treatments such as androgen deprivation.

IMMUNOTHERAPY
The team will investigate the use of the monoclonal antibody ipilimumab as part of the immunotherapeutic treatment. This antibody can cause the body's own immune system to react against cancer cells. Prof. Krainer said that "the use of ipilimumab rather than docetaxel has led to rather surprising successes during the past year in a small-scale trial. In three patients, a tumor that had been hard to treat became so small that it could be surgically removed. Since a small-scale trial of this nature only allows limited claims to be made about the drug, ipilimumab is now being investigated further in a larger study."
HORMONE THERAPY
A hormone treatment based on the drug MDV3100 is also being trialed by the team at the Medical University of Vienna. This is used as a second-line treatment after the initial treatment with docetaxel. MDV3100 is a substance that blocks the androgen receptor and thus offers a new approach to the prevention of hormone dependent tumor growth.
AUGMENTED STANDARD TREATMENT
In the past, Prof. Krainer and his team were able to show the efficacy of docetaxel versus other common chemotherapeutic drugs. The third trial at the Medical University of Vienna will test the combination of docetaxel with the tyrosine kinase inhibitor sunitinib. As part of the trial, the researchers will examine biomarkers in the patients' blood that will yield information about the progress of the treatment.
TOP QUALITY RESEARCH IN AUSTRIA
"We are delighted that multinational pharmaceutical companies find in Austria the optimal environment and competent partners for clinical trials and basic research", said Dr. René Siegl, Managing Director of the Austrian investment promotion company ABA - Invest in Austria. "This shows that the conditions at the location Austria are ideal". More than 15 percent of Austrian R&D expenditure comes from foreign commissions. With 2.73 percent of the GNP in 2009 being spent on research, Austria has closed the gap with other European countries at the forefront of innovation. The aim is a research quota of 4 percent by 2020. In future Austria will create even greater incentives for businesses to attract innovation centers and will further develop collaborative endeavors between the scientific and business worlds.

For further information please contact:

Hanni Grassauer
ABA - Invest in Austria
Opernring 3
1010 Wien, Austria
T +43 / 1 / 588 58 57
F +43 / 1 / 586 86 59
E h.grassauer@aba.gv.at
Mag. Marta Korinkova
PR-Assistentin & Office Managerin
PR&D - Public Relations für Forschung & Bildung
T +43 1 505 70 44
F +43 1 505 50 83
E korinkova@prd.at
Campus Vienna Biocenter 2
1030 Vienna, Austria

Marta Korinkova | PR&D
Further information:
http://www.investinaustria.at
http://www.prd.at

More articles from Life Sciences:

nachricht Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)

nachricht CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>